Overview
What is Subcutaneous Drug Development & Delivery Consortium Inc?
Subcutaneous Drug Development & Delivery Consortium Inc, based in Beaverton, Oregon, is a nonprofit organization with a focus on addressing challenges and seizing opportunities in the field of subcutaneous drug dosage and delivery. Their mission is to collaboratively advance this area in a non-competitive manner. They are currently involved in a research project titled 'Development of In Vitro, Preclinical, and In Silico Models to Predict the Human Subcutaneous Absorption and Overall Bioavailability of MABs'. This project aims to create models that can predict the human subcutaneous absorption and overall bioavailability of monoclonal antibodies (MABs), which could significantly impact the development and delivery of subcutaneous drugs.
Official website here: www.subcutaneousconsortium.org
Is Subcutaneous Drug Development & Delivery Consortium Inc legitimate?
Subcutaneous Drug Development & Delivery Consortium Inc is a legitimate nonprofit organization registered as a 501(c)(6) entity. Subcutaneous Drug Development & Delivery Consortium Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $0
Professional Fundraising Fees: $0
Other Salaries and Wages: $0
For more financial information, click here
Official website here: www.subcutaneousconsortium.org
What is the mission statement of Subcutaneous Drug Development & Delivery Consortium Inc?
The Subcutaneous Drug Development & Delivery Consortium Inc's mission is centered around collaboratively addressing the most significant challenges and opportunities in subcutaneous dosage and delivery. This is done in a precompetitive manner, aiming to advance the field without creating competition among its members.
The organization is actively engaged in a project titled 'Bioavailability Collaborative Research,' which includes the development of in vitro, preclinical, and in silico models to predict the human subcutaneous absorption and overall bioavailability of monoclonal antibodies (MABS). This research aim is part of their broader mission to contribute to the advancement of subcutaneous drug delivery methods.
Official website here: www.subcutaneousconsortium.org
Who is the CEO of Subcutaneous Drug Development & Delivery Consortium Inc?
Donna French is the President of Subcutaneous Drug Development & Delivery Consortium Inc.
Official website here: www.subcutaneousconsortium.org
What is the revenue of Subcutaneous Drug Development & Delivery Consortium Inc?
Subcutaneous Drug Development & Delivery Consortium Inc's revenue in 2022 was $406,250.
Official website here: www.subcutaneousconsortium.org
Who are the executives of Subcutaneous Drug Development & Delivery Consortium Inc and what are their salaries?
There 3 volunteers at Subcutaneous Drug Development & Delivery Consortium Inc.
Here are 3 key members and their salaries:
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Official website here: www.subcutaneousconsortium.org
Where can I find the form 990 for Subcutaneous Drug Development & Delivery Consortium Inc?
Subcutaneous Drug Development & Delivery Consortium Inc's most recent form 990 was submitted in 2022 and can be accessed here.
Official website here: www.subcutaneousconsortium.org
Learn more at the official website: www.subcutaneousconsortium.org
Mission Statement of Subcutaneous Drug Development & Delivery Consortium Inc
Subcutaneous Drug Development & Delivery Consortium Inc, a collaborative organization, is dedicated to proactively addressing the most significant challenges and opportunities in subcutaneous drug dosage and delivery. Their mission is to foster a precompetitive environment, promoting collective advancement in this field. The Consortium is currently engaged in a research project titled 'Bioavailability Collaborative Research Project: Development of In Vitro, Preclinical, and In Silico Models to Predict the Human Subcutaneous Absorption and Overall Bioavailability of Mabs'. This project aims to establish predictive models for subcutaneous absorption and overall bioavailability of monoclonal antibodies (Mabs), which could significantly contribute to the development of more effective drug delivery systems in the future.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
Subcutaneous Drug Development & Delivery Consortium Inc plays a vital role in enhancing the field of drug delivery, specifically focusing on subcutaneous administration. By fostering collaboration among stakeholders, the consortium addresses pressing challenges and opportunities in this area through a precompetitive framework. This approach allows for the pooling of resources and knowledge, facilitating advancements that may not be achievable independently.
The consortium’s initiatives, such as the Bioavailability Collaborative Research Project, aim to develop robust in vitro, preclinical, and in silico models. These models are crucial for accurately predicting human subcutaneous absorption and overall bioavailability of monoclonal antibodies (mAbs). Through this research, the consortium enhances the understanding of how drugs are absorbed and utilized in the body, which is critical for optimizing therapeutic efficacy.
By tackling these significant issues in subcutaneous dosage and delivery, the consortium contributes to improved patient outcomes, greater accessibility to effective therapies, and a more efficient drug development process.
This information is meant to be a general summary of Subcutaneous Drug Development & Delivery Consortium Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Program Service Revenue: $406,250
- Gross Receipts: $406,250
Assets and Liabilities:
- Total Assets: $685,644
- Total Liabilities: $50,941
- Net Assets: $634,703
Want to help this charity, for free? You can click here to learn more about Give Freely
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
MEMBERSHIP DUES
Revenue
$406,250
Organization Details
Founding Year
2020
Phone
(503) 619-0505Principal Officer
Donna French
Main Address
3855 SW 153RD DRIVE, BEAVERTON, OR, 97003
NTEE Category
Code: S46 - Community improvement
If you are a representative of Subcutaneous Drug Development & Delivery Consortium Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.